OpenURL Connection Search

Select item for more details and to access through your institution.

IL16 PRODUCTION IS A MECHANISM OF RESISTANCE TO BTK INHIBITORS AND TO R‐CHOP.
Published in:
Hematological Oncology, 2023, v. 41, p. 188, doi. 10.1002/hon.3163_118
By:
- Arribas, A.;
- Napoli, S.;
- Cascione, L.;
- Sartori, G.;
- Cannas, E.;
- Tarantelli, C.;
- Spriano, F.;
- Gaudio, E.;
- Zucchetto, A.;
- Rossi, F. M.;
- Rinaldi, A.;
- Castro de Moura, M.;
- Jovic, S.;
- Pittau, R. Bordone;
- Stathis, A.;
- Stussi, G.;
- Gattei, V.;
- Brown, J. R.;
- Esteller, M.;
- Zucca, E.
Publication type:
Article
THE ANTIBODY‐DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT‐402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI‐LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION.
Published in:
Hematological Oncology, 2019, v. 37, p. 129, doi. 10.1002/hon.90_2629
By:
- Tarantelli, C.;
- Spriano, F.;
- Golino, G.;
- Gaudio, E.;
- Scalise, L.;
- Cascione, L.;
- Zucca, E.;
- Berkel, P.;
- Stathis, A.;
- Zammarchi, F.;
- Bertoni, F.
Publication type:
Article
EG‐011 IS A NOVEL SMALL MOLECULE WITH IN VITRO AND IN VIVO ANTI‐TUMOR ACTIVITY AGAINST LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 513, doi. 10.1002/hon.197_2631
By:
- Gaudio, E.;
- Spriano, F.;
- Tarantelli, C.;
- Guala, M.;
- Riveiro, E.;
- Golino, G.;
- Lupia, A.;
- Costa, G.;
- Rocca, R.;
- Cascione, L.;
- Jenni, S.;
- Tsai, Y.;
- Bornhauser, B.;
- Alcaro, S.;
- Paduano, F.;
- Trapasso, F.;
- Zucca, E.;
- Stathis, A.;
- Pazzi, N.;
- Cavalli, F.
Publication type:
Article
SIMULTANEOUS BET/CREBBP/EP300 TARGETING APPROACH COMPARED TO SINGLE BET OR CREBBP/EP300 INHIBITION IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL).
Published in:
Hematological Oncology, 2019, v. 37, p. 512, doi. 10.1002/hon.196_2631
By:
- Spriano, F.;
- Gaudio, E.;
- Tarantelli, C.;
- Golino, G.;
- Cascione, L.;
- Zucca, E.;
- Stathis, A.;
- Giles, F.;
- Bertoni, F.
Publication type:
Article
THE FIRST‐IN‐CLASS ETS INHIBITOR TK‐216 INTERFERES WITH ETS TRANSCRIPTION FACTORS AND SYNERGIZE WITH LENALIDOMIDE IN LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 322, doi. 10.1002/hon.132_2630
By:
- Spriano, F.;
- Chung, E.;
- Napoli, S.;
- Tarantelli, C.;
- Gaudio, E.;
- Cascione, L.;
- Cavalli, A.;
- Rinaldi, A.;
- Kwee, I.;
- Ye, H.;
- Rossi, D.;
- Zucca, E.;
- Stathis, A.;
- Jessen, K.;
- Lannutti, B.;
- Toretsky, J.;
- Bertoni, F.
Publication type:
Article
THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES.
Published in:
Hematological Oncology, 2019, v. 37, p. 323, doi. 10.1002/hon.134_2630
By:
- Spriano, F.;
- Tarantelli, C.;
- Golino, G.;
- Gaudio, E.;
- Scalise, L.;
- Cascione, L.;
- Zucca, E.;
- Van Berkel, P.;
- Stathis, A.;
- Zammarchi, F.;
- Bertoni, F.
Publication type:
Article
MECHANISMS OF SECONDARY RESISTANCE TO IDELALISIB IN MARGINAL ZONE LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 319, doi. 10.1002/hon.128_2630
By:
- Arribas, A.;
- Napoli, S.;
- Gaudio, E.;
- Cascione, L.;
- Di Veroli, A.;
- Tarantelli, C.;
- Spriano, F.;
- Zucchetto, A.;
- Rossi, F.;
- Rinaldi, A.;
- Stathis, A.;
- Stussi, G.;
- Gattei, V.;
- Cruciani, G.;
- Zucca, E.;
- Rossi, D.;
- Bertoni, F.
Publication type:
Article
COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS.
Published in:
Hematological Oncology, 2019, v. 37, p. 318, doi. 10.1002/hon.127_2630
By:
- Tarantelli, C.;
- Lange, M.;
- Gaudio, E.;
- Cascione, L.;
- Spriano, F.;
- Kwee, I.;
- Arribas, A.;
- Rinaldi, A.;
- Jourdan, T.;
- Berthold, M.;
- Margheriti, F.;
- Gritti, G.;
- Rossi, D.;
- Stathis, A.;
- Liu, N.;
- Zucca, E.;
- Politz, O.;
- Bertoni, F.
Publication type:
Article
THE ANTIBODY‐DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT‐402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI‐LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION.
Published in:
Hematological Oncology, 2019, v. 37, p. 129, doi. 10.1002/hon.90_2629
By:
- Tarantelli, C.;
- Spriano, F.;
- Golino, G.;
- Gaudio, E.;
- Scalise, L.;
- Cascione, L.;
- Zucca, E.;
- Berkel, P.;
- Stathis, A.;
- Zammarchi, F.;
- Bertoni, F.
Publication type:
Article
EG‐011 IS A NOVEL SMALL MOLECULE WITH IN VITRO AND IN VIVO ANTI‐TUMOR ACTIVITY AGAINST LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 513, doi. 10.1002/hon.197_2631
By:
- Gaudio, E.;
- Spriano, F.;
- Tarantelli, C.;
- Guala, M.;
- Riveiro, E.;
- Golino, G.;
- Lupia, A.;
- Costa, G.;
- Rocca, R.;
- Cascione, L.;
- Jenni, S.;
- Tsai, Y.;
- Bornhauser, B.;
- Alcaro, S.;
- Paduano, F.;
- Trapasso, F.;
- Zucca, E.;
- Stathis, A.;
- Pazzi, N.;
- Cavalli, F.
Publication type:
Article
SIMULTANEOUS BET/CREBBP/EP300 TARGETING APPROACH COMPARED TO SINGLE BET OR CREBBP/EP300 INHIBITION IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL).
Published in:
Hematological Oncology, 2019, v. 37, p. 512, doi. 10.1002/hon.196_2631
By:
- Spriano, F.;
- Gaudio, E.;
- Tarantelli, C.;
- Golino, G.;
- Cascione, L.;
- Zucca, E.;
- Stathis, A.;
- Giles, F.;
- Bertoni, F.
Publication type:
Article
THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES.
Published in:
Hematological Oncology, 2019, v. 37, p. 323, doi. 10.1002/hon.134_2630
By:
- Spriano, F.;
- Tarantelli, C.;
- Golino, G.;
- Gaudio, E.;
- Scalise, L.;
- Cascione, L.;
- Zucca, E.;
- Van Berkel, P.;
- Stathis, A.;
- Zammarchi, F.;
- Bertoni, F.
Publication type:
Article
THE FIRST‐IN‐CLASS ETS INHIBITOR TK‐216 INTERFERES WITH ETS TRANSCRIPTION FACTORS AND SYNERGIZE WITH LENALIDOMIDE IN LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 322, doi. 10.1002/hon.132_2630
By:
- Spriano, F.;
- Chung, E.;
- Napoli, S.;
- Tarantelli, C.;
- Gaudio, E.;
- Cascione, L.;
- Cavalli, A.;
- Rinaldi, A.;
- Kwee, I.;
- Ye, H.;
- Rossi, D.;
- Zucca, E.;
- Stathis, A.;
- Jessen, K.;
- Lannutti, B.;
- Toretsky, J.;
- Bertoni, F.
Publication type:
Article
MECHANISMS OF SECONDARY RESISTANCE TO IDELALISIB IN MARGINAL ZONE LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 319, doi. 10.1002/hon.128_2630
By:
- Arribas, A.;
- Napoli, S.;
- Gaudio, E.;
- Cascione, L.;
- Di Veroli, A.;
- Tarantelli, C.;
- Spriano, F.;
- Zucchetto, A.;
- Rossi, F.;
- Rinaldi, A.;
- Stathis, A.;
- Stussi, G.;
- Gattei, V.;
- Cruciani, G.;
- Zucca, E.;
- Rossi, D.;
- Bertoni, F.
Publication type:
Article
COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS.
Published in:
Hematological Oncology, 2019, v. 37, p. 318, doi. 10.1002/hon.127_2630
By:
- Tarantelli, C.;
- Lange, M.;
- Gaudio, E.;
- Cascione, L.;
- Spriano, F.;
- Kwee, I.;
- Arribas, A.;
- Rinaldi, A.;
- Jourdan, T.;
- Berthold, M.;
- Margheriti, F.;
- Gritti, G.;
- Rossi, D.;
- Stathis, A.;
- Liu, N.;
- Zucca, E.;
- Politz, O.;
- Bertoni, F.
Publication type:
Article
COMBINATORIAL SCREENING OF THE PI3K INHIBITOR COPANLISIB IN T CELL LYMPHOMAS.
Published in:
Hematological Oncology, 2017, v. 35, p. 256, doi. 10.1002/hon.2438_122
By:
- Gaudio, E.;
- Kwee, I.;
- Spriano, F.;
- Tarantelli, C.;
- Rinaldi, A.;
- Jourdan, T.;
- Berthold, M.;
- Arribas, A.;
- Stathis, A.;
- Rossi, D.;
- Liu, N.;
- Lange, M.;
- Politz, O.;
- Zucca, E.;
- Bertoni, F.
Publication type:
Article

Found: 16